High Growth Tech Stocks To Watch In January 2025

In This Article:

As we enter January 2025, global markets are showing signs of optimism with cooling inflation and strong bank earnings driving U.S. stocks higher, while European markets benefit from slower-than-expected inflation potentially leading to rate cuts. In this environment, investors might look for high growth tech stocks that can capitalize on these favorable conditions by demonstrating robust innovation and adaptability in a rapidly evolving market landscape.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Shanghai Baosight SoftwareLtd

21.82%

25.22%

★★★★★★

Seojin SystemLtd

35.41%

39.86%

★★★★★★

Clinuvel Pharmaceuticals

21.39%

26.17%

★★★★★★

eWeLLLtd

26.41%

28.82%

★★★★★★

Yggdrazil Group

30.20%

87.10%

★★★★★★

Medley

20.97%

27.22%

★★★★★★

Mental Health TechnologiesLtd

25.83%

113.12%

★★★★★★

Fine M-TecLTD

36.52%

135.02%

★★★★★★

JNTC

29.48%

104.37%

★★★★★★

Dmall

29.53%

88.37%

★★★★★★

Click here to see the full list of 1225 stocks from our High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Valneva

Simply Wall St Growth Rating: ★★★★★☆

Overview: Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet needs, with a market cap of €363.71 million.

Operations: Valneva SE generates revenue primarily through the development, manufacturing, and commercialization of vaccines targeting infectious diseases with unmet needs. As a specialty vaccine company, it focuses on creating prophylactic solutions to address these health challenges.

Valneva SE, navigating through a challenging biotech landscape, has shown promising strides with an expected annual revenue growth of 22.5%, significantly outpacing the French market's 5.5%. Despite currently being unprofitable, the company is projected to shift towards profitability within three years, buoyed by a robust 4.63% forecast in earnings growth annually. Recent strategic moves include a licensing agreement with Serum Institute of India to distribute its chikungunya vaccine in Asia amidst one of India’s worst outbreaks, reflecting not only immediate response capabilities but also long-term market penetration strategies supported by substantial funding from CEPI and the EU totaling $41.3 million. These developments underscore Valneva's proactive approach in expanding its global footprint while enhancing shareholder value through targeted R&D investments and strategic partnerships.